swine flu: Country pay € 8.33 for each unused dose = (8 , 33 x 650 000 = € 5.4145 million here
hence discarded at € 283.22 million ... daat ass after everything normal ?????
The members of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute are in their vaccination recommendation for the new influenza A is not influenced by financial contributions from the pharmaceutical industry has been.
said that the federal government in response to an inquiry by the Group The Left (printed matter number 17/328). "members of the STIKO in which the concern of bias due to some projects financed by vaccine manufacturers the new influenza A was to have the recommendation for vaccination against the novel influenza A is not involved, "says the document.
subject also no evidence of a possible influence of the WTO decision by the pharmaceutical industry, which has led to an increase in the pandemic alert level from 5 to 6 in June 2009.
Overall, the states for any unused doses of 8.33 euros to the manufacturer GlaxoSmithKline (GSK) to pay. The amount consists of one euro for the antigen, the adjuvant for six euros and 1.33 euros for VAT together.
The originally ordered quantity of 50 million doses was at a Talk between individual provinces and GSK to 34 million doses reduced. GSK therefore receive a purchase price of € 283.22 million.
same time the government made it clear that the federal government the demand of the countries will not meet to take the economic risk in respect of unused doses. "Ensuring sufficient availability of vaccine in an influenza pandemic is an object of the countries," it says in the response.
for the performance of their duties therefore, the countries of the expenditures and thus the financial risk that not all doses were inoculated and funded through health insurance.
The government pointed out that the countries have been completed because of fears that supply shortages if supply contracts with two manufacturers: GSK and Novartis. As the population had only cautiously be vaccinated, the agreement with Novartis did not have to be raised.
are According to the Federal Government requests from States, and such private intermediaries and wholesalers who want to buy the Impfkontingente of the countries. Currently, the requests were from the state of Lower Saxony, which currently holds the presidency of the Conference of Health Ministers, tested for their resilience. ©
fos / aerzteblatt.de
0 comments:
Post a Comment